The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Effects of Brain-derived Neurotrophic Factor on 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in Monkeys
Abstract
The effects of intrathecal infusion of brain-derived neurotrophic factor (BDNF) were examined in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian model in monkeys. Nine Japanese monkeys were divided randomly into three groups, an untreated control (n = 3), a BDNF group (n = 3), and a non-BDNF group (n = 3). Animals in the BDNF group received continuous intrathecal infusion of 10 ml of cell culture medium containing 10 micrograms of BDNF protein; the non-BDNF group received intrathecal infusion of the same culture medium without BDNF. To induce parkinsonian syndromes, a total of 1 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine was administered intravenously to each monkey in both the BDNF and non-BDNF groups. The neurological signs in the monkeys were monitored for 2 weeks and were scored according to the monkey parkinsonism rating scale; histological changes in the substantia nigra were evaluated after the 2-week observation period. The BDNF-treated animals remained asymptomatic during the 1st week and showed mild parkinsonism during the 2nd week, whereas the non-BDNF group showed typical parkinsonian syndrome during the 1st week, with deterioration in the 2nd week. Histological damage in the substantia nigra correlated well with the clinical features. Severe neuronal cell loss in the substantia nigra was observed in animals with severe parkinsonism (those in the non-BDNF group), whereas significantly less damage was observed in this region in the BDNF group.(ABSTRACT TRUNCATED AT 250 WORDS)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal models of Parkinson’s disease (PD), BDNF enhances the survival of dopaminergic neurons, improves dopaminergic neurotransmission and motor performance.”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [89]
In the citing paper
“In the case of alternations in behavior, the studies on monkeys revealed significantly less severe symptoms of PD in animals treated with BDNF [89].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [89]
In the citing paper
“In the vast majority of studies with BDNF administration before induction of parkinsonism, the research results revealed at least partial prevention of neuronal cell loss [89,90,92,93,99,101].”
From BDNF as a Promising Therapeutic Agent in Parkinson’s Disease (2020) · cites this paper as [89]
Citations
Cites
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Purification of a new neurotrophic factor from mammalian brain.
Barde, Y. A., Edgar, D., & Thoenen, H. (1982) · The EMBO Journal · doi:10.1002/j.1460-2075.1982.tb01207.x · Cited by 1,822
BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra
Hyman, C., Hofer, M., Barde, Y., Juhasz, M., Yancopoulos, G. D., Squinto, S. P., & Lindsay, R. M. (1991) · Nature · doi:10.1038/350230a0 · Cited by 1,503
The trk Proto-Oncogene Product: a Signal Transducing Receptor for Nerve Growth Factor
Kaplan, D. R., Hempstead, B. L., Martin-Zanca, D., Chao, M. V., & Parada, L. F. (1991) · Science · doi:10.1126/science.1850549 · Cited by 1,379
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,377
Nicklas, W. J., Vyas, I. L., & Heikkila, R. E. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90146-8 · Cited by 1,273
Hohn, A., Leibrock, J., Bailey, K., & Barde, Y.-A. (1990) · Nature · doi:10.1038/344339a0 · Cited by 1,145
Kaplan, D. R., Martı́n-Zanca, D., & Parada, L. F. (1991) · Nature · doi:10.1038/350158a0 · Cited by 1,059
Langston, J. W., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Research works printed but not linked: 1
- Burns, 1983, A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Proc Natl Acad Sci U S A, 80, 4546, 10.1073/pnas.80.14.4546 · DOI
Cited by
Sorted by citations
Items 101–134 of 134
Ishikawa, K., Yasuda, S., Fukuhara, K., Iwanaga, Y., Ida, Y., Ishikawa, J., Yamagata, H., Ono, M., Kakeda, T., & Ishikawa, T. (2014) · Neuroreport · doi:10.1097/wnr.0000000000000072 · Cited by 21
Cunningham, M. G., Bolay, H., Scouten, C. W., Moore, C. I., Jacoby, D. B., Moskowitz, M. A., & Sørensen, J. C. H. (2004) · Neurosurgery · doi:10.1227/01.neu.0000125007.03145.00 · Cited by 21
Activation of TrkB receptors by NGFβ mimetic peptide conjugated polymersome nanoparticles
Roy, S., Johnston, A. H., Moin, S. T., Dudás, J., Newman, T. A., Hausott, B., Schrott‐Fischer, A., & Glueckert, R. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.12.005 · Cited by 20
Lara, J., Kusano, K., House, S. B., & Gainer, H. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(02)00028-6 · Cited by 20
Genetic Insights into the Molecular Pathophysiology of Depression in Parkinson’s Disease
Angelopoulou, E., Bougea, A. M., Paudel, Y. N., GEORGAKOPOULOU, V. E., Papageorgiou, S. G., & Piperi, C. (2023) · Medicina · doi:10.3390/medicina59061138 · Cited by 19
Schmidt, F., Douaron, G. L., Champy, P., Amar, M., Séon‐Méniel, B., Raisman‐Vozari, R., & Figadère, B. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.05.067 · Cited by 19
Aliaga, E., Cárcamo, C., Abarca, J., Tapia‐Arancibia, L., & Bustos, G. A. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00095-4 · Cited by 19
Fernandes, A. R., & Chari, D. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.039 · Cited by 17
Are growth factors the answer?
Ramaswamy, S., & Kordower, J. H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70809-0 · Cited by 17
BDNF-Regulated Modulation of Striatal Circuits and Implications for Parkinson’s Disease and Dystonia
Wolf, D. L., Ayon-Olivas, M., & Sendtner, M. (2024) · Biomedicines · doi:10.3390/biomedicines12081761 · Cited by 18
Er, Ş., & Airavaara, M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220770 · Cited by 14
Pawar, G. N., Parayath, N. N., Sharma, A., Coito, C., Khorkova, O., Hsiao, J. H., Curry, W. T., Amiji, M. M., & Bleier, B. S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.660841 · Cited by 14
Rosa, J. S., Hamel, K. A., Soles, A., Sheeler, C. A., Borgenheimer, E., Gilliat, S., Sbrocco, K., Ghannoum, F. J., Handler, H. P., Forster, C. L., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106023 · Cited by 13
Tsai, S. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.04.014 · Cited by 12
Pizarro, J. M., Chang, W. E., Bah, M. J., Wright, L. K. M., Saviolakis, G. A., Alagappan, A., Robison, C. L., Shah, J., Meyerhoff, J. L., Cerasoli, D. M., et al. (2012) · Toxicological Sciences · doi:10.1093/toxsci/kfr353 · Cited by 12
Riquelme, E., Abarca, J., Campusano, J. M., & Bustos, G. A. (2012) · Parkinson s Disease · doi:10.1155/2012/129605 · Cited by 11
Gene therapy for Parkinson’s disease
Le, H., & Frim, D. M. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.2.151 · Cited by 10
O’Neill, M. J., Messenger, M. J., Lakics, V., Murray, T. K., Karran, E. H., Szekeres, P. G., Nisenbaum, E. S., & Merchant, K. (2006) · International review of neurobiology · doi:10.1016/s0074-7742(06)77006-4 · Cited by 10
Disease modifying therapies for Parkinson's disease: Novel targets
Vijiaratnam, N., & Foltynie, T. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108839 · Cited by 6
Increasing Effect of Citrus natsudaidai on Brain-Derived Neurotrophic Factor
Nakajima, K., Okubo, S., & Oiso, S. (2023) · Journal of Oleo Science · doi:10.5650/jos.ess22324 · Cited by 6
From Man to Mouse: The MPTP Model of Parkinson Disease
Jackson-Lewis, V. R., & Smeyne, R. J. (2005) · Elsevier eBooks · doi:10.1016/b978-012088382-0/50012-8 · Cited by 5
Jackson-Lewis, V., Lester, D. B., Kozina, E. A., Przedborski, S., & Smeyne, R. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-405195-9.00017-2 · Cited by 5
The therapeutic use of clonal neural stem cells in experimental Parkinson´s disease
Nelke, A., García‐López, S., Caso, J. R., & Pereira, M. P. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03965-0 · Cited by 4
PEG-Free Polyion Complex Nanocarriers for Brain-Derived Neurotrophic Factor
Fay, J. M., Lim, C., Finkelstein, A., Batrakova, E. V., & Kabanov, A. V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071391 · Cited by 4
Neurotrophic factors for the investigation and treatment of movement disorders
de Yébenes, J. G., Sánchez, M. P., & Mena, M. A. (2003) · Neurotoxicity Research · doi:10.1007/bf03033377 · Cited by 4
Neurotrophic factors and Parkinson's disease
Gash, D. M., Chen, Y., & Gerhardt, G. A. (2007) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)83025-9 · Cited by 3
The Causative and Curative Roles of Brain-Derived Neurotrophic Factor in Parkinson’s Disease
Hernández-Baltazar, D., Nadella, R., Llanderal, T. C., Puga-Olguín, A., Barrientos-Bonilla, A. A., Zavala-Flores, L. M., Villanueva-Olivo, A., Sánchez-García, A. D. C., Rovirosa-Hernández, M. D. J., & Rembao-Bojórquez, J. D. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.81215 · Cited by 4
Shiu, F. H., Skelton, H. M., Berglund, K., Fernandez, A. M., Gutekunst, C., Robinson, E. R., Wang, Z., & Gross, R. E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.17.512538 · Cited by 2
Epigenomics of neurological disorders
Khorkova, O., Hsiao, J. H., & Wahlestedt, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00003-9 · Cited by 1
Substantia Nigra Modulation by Essential Fatty Acids
Andrade‐da‐Costa, B. L. D. S., Passos, P. P., Cardoso, H. D., Gonçalves‐Pimentel, C., dos Santos, E. F., Borba, J. M. C., & Guedes, R. C. A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410527-0.00020-x
Cell-Based Therapies for Parkinson’s Disease: Preclinical and Clinical Perspectives
Sebastiano, A. R. D., Staudt, M. D., Benoit, S. M., Xu, H., Hebb, M. O., & Schmid, S. (2016) · InTech eBooks · doi:10.5772/63747
Galati, D. F. (2013) · CU Scholar (University of Colorado Boulder)
Block Ionomer Complex Formulations For In Vivo Protein Delivery
Jiang, Y. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/x27r-1j68
A De Novo Peptide That Induces Axonal Growth Through TrkB Activation
Maini, R., Tamada, K., Fukuda, K., Takumi, T., & Suga, H. (2026) · ChemBioChem · doi:10.1002/cbic.70517
Metadata
- Authors
- Tsukahara, T., Takeda, M., Shimohama, S., Ohara, O., & Hashimoto, N.
- Affiliations
- National Cerebral and Cardiovascular Center (JP)
- Kyoto University (JP)
- Shionogi (Japan) (JP)
- Venue
- Neurosurgery
- Published
- 1995-10-01
- Volume
- 37
- Issue
- 4
- Pages
- 733-741
- ISSN
- 0148-396X (ISSN-L)
- 1524-4040
- OpenAlex
- W1976999555
- Cited by
- 134
- References
- 60
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 6 · 2022: 3 · 2021: 5 · 2020: 8 · 2019: 8 · 2018: 7 · 2016: 9 · 2015: 3 · 2014: 8 · 2013: 6 · 2012: 10
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurosurgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- brain-derived neurotrophic factor, Parkinson's disease, MPTP-induced parkinsonism, intrathecal infusion, substantia nigra, neuronal loss, neuroprotection, monkey model
- MeSH terms
- Animals, Brain, Macaca, Nerve Degeneration, Nerve Growth Factors, Nerve Tissue Proteins, Neurologic Examination, Parkinson Disease, Secondary, Substantia Nigra, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
